Home›Companies›Biotech & Pharma›Terremoto

Terremoto Biosciences, Inc.

Develops targeted medicines for patients with cancer and genetic diseases.

Updated Nov 10, 2026·Latest SEC filing Apr 22, 2026·Suggest an edit

About Terremoto

Terremoto is a private company based in South San Francisco, California, incorporated in 2022 in Delaware. It has reported $40,725,000 raised in one offering on Form D since April 2026. Its chief executive is James Christensen.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 10, 2026Apr 22, 2026$40,725,000of $108.5M target14$2.9MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Terremoto's Form D filed Apr 22, 2026.

MG
GL
Grace Lu
Executive officer
James Christensen
James Christensen
President and Chief Executive Officer, director
Reid Huber
Reid Huber
Partner, Third Rock Ventures and director
Peter Thompson
Peter Thompson
Co-founder and Director, Terremoto
Charles Baum
Charles Baum
Executive Chairman
Also a director at Odyssey Therapeutics.

Sources

  1. SECTerremoto Biosciences, Inc. filing history
  2. CompanyAbout Terremoto
  3. CompanyContact Terremoto